missing translation for 'onlineSavingsMsg'
Learn More

Gibco™ PeproGMP™ Human VEGF-165 Recombinant Protein, PeproTech®

Numéro de catalogue. 502558489
Modifier l'affichage
Click to view available options
Quantité:
100 μg
50 μg
1 mg
3 product options available for selection
Product selection table with 3 available options. Use arrow keys to navigate and Enter or Space to select.
Numéro de catalogue. Quantité
502558489 1 mg
502558490 100 μg
01672621 50 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 3 options available.
3 options
Numéro de catalogue. 502558489 Fournisseur Gibco™ Code fournisseur GMP100201MG

Pour de l'aide SVP utiliser la function de clavardage; nous envoyer un couriel à help@thermofisher.com ou appelez le service à la clientèle au 1-800-234-7437.

Recombinant Protein

PeproTech Recombinant Human VEGF-165 is a 38.2 kDa, disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains. PeproGMP VEGF-165 can be used with PeproGMP BMP-4 and PeproGMP SCF in CTS StemScale medium for pluripotent stem cell differentiation, specifically for mesoderm and hematopoetic progenitor cell induction. Reconstitute using sterile water (i.e., WFI) to a concentration of 0.1-1.0 mg/ml. Additional product information, specifications, handling and reconstitution information are provided on the Certificate of Analysis. All PeproGMP™ products are manufactured using animal-derived component free materials. Product Description/Intended Use: PeproTech GMP recombinant proteins are manufactured for use as ancillary materials by applying applicable principles of GMP and quality control requirements from USP (United States Pharmacopeia) Chapter 1043 Ancillary Materials for Cell, Gene, and Tissue-Engineered Products.

The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.

Spécifications

Numéro d'enregistrement P15692
À utiliser avec (application) Control, Western Blot Control, Bioactivity
Formule Protein with no preservative
ID du gène (Entrez) 7422
Poids moléculaire (g/mol) 38.2 kDa
Nom PeproGMP™ Human VEGF-165
Méthode de purification Purified
Quantité 1 mg
Conditions de stockage -20°C or -80°C if preferred
Statut réglementaire GMP
Concentration en endotoxines ≤0.1 EU/μg
Alias du gène H-VEGF-165; MVCD1; M-VEGF-165; vascular endothelial growth factor 165b; vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; vascular permeability factor; VEGF; VEGF164; VEGF165; Vegfa; VEGF-A; VPF
Nom usuel VEGF-165
Symbole de gène Vegfa
Type de produit Protein
Conjugué Unconjugated
Recombinant Recombinant
Séquence APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
Activité Determined by the proliferation of HUVECs.
Système d’expression E. coli
Forme Lyophilized
Grade de qualité ou de pureté ≥ 98% by SDS-PAGE gel and HPLC analyses.
Afficher plus de résultats Afficher moins de résultats